MedTrace Logo

Dexmedetomidine Versus Dexamethasone as Adjuncts in Erector Spinae Plane Block in Modified Radical Mastectomy

NCT05447949 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-07-07

No results posted yet for this study

Summary

The aim of this study is to evaluate the analgesic efficacy and safety of adding dexmedetomidine versus dexamethasone to levobupivacaine in ultrasound guided ESPB for patients undergoing modified radical mastectomy

Conditions

Interventions

PROCEDURE

Adjuncts to levobupivacaine in Erector Spinae Plane Block

The block level will be at T5 with the patient in a sitting position and full aseptic precautions. T5 transverse process; these are recognizable as flat, squared-off acoustic shadows with only a very faint image of the pleura visible. In a longitudinal US view, in which the following layers will be visible superficial to the transverse processes: skin, subcutaneous tissue, trapezius, erector spinae muscle . Skin is topicalized, then echogenic block needle inserted in plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. After aspiration; to avoid intravascular injection, 30 ml of injectate is injected and separation will be seen. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm will be used (18-19).

Sponsors & Collaborators

  • National Cancer Institute, Egypt

    lead OTHER

Principal Investigators

  • Ashgan R Ali, Professor · Anaesthesiology Faculty of Medicine - Cairo University

  • Heba I Ahmed, Ass. Professor · Anaesthesiology Faculty of Medicine - Cairo University

  • Reham M Gamal, Lecturer · Anaesthesiology National Cancer Institute - Cairo University

  • Mohammed M Abdelrahman, Ass. Lecturer · Anaesthesiology National Cancer Institute - Cairo University

  • Norhan H El Emam, Resident · Anaesthesiology National Cancer Institute - Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-15
Primary Completion
2022-03-15
Completion
2022-03-15

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05447949 on ClinicalTrials.gov